MDFA welcomes news that Ozurdex will be listed on the Pharmaceutical Benefits Scheme (PBS) from November 2016.
Read MoreSusan regrets not having regular eye tests. If her diabetic eye disease was picked up earlier, she may not have lost her sight.
Read MoreMacular Disease Foundation Australia has responded to the Independent Review of the NDIS Act.
Read MoreMDFA says the addition of ranibizumab (Lucentis) to the Pharmaceutical Benefits Scheme provides patients with affordable access to treatment for diabetic macular oedema and retinal vein occlusion.
Read MoreMDFA has voiced its concern regarding the economic impact of diabetic macular oedema (DMO) in Australia.
Read MoreWe’ve audited the six largest health funds to find out the benefits they offer for low vision aids and technology.
Read MoreAustralians affected by diabetes are being urged to take regular eye tests to reduce the risk of serious vision loss or blindness.
Read MoreAfter extensive lobbying by MDFA, SA Health has confirmed funding for an additional seven eye clinics per month.
Read More